Hippomectin 12 mg/g oraaligeeli Suomi - suomi - Fimea (Suomen lääkevirasto)

hippomectin 12 mg/g oraaligeeli

le vet. b.v. - ivermectin - oraaligeeli - 12 mg/g - ivermektiini

OXAPLAMYL 5 mg/ml infuusiokonsentraatti, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

oxaplamyl 5 mg/ml infuusiokonsentraatti, liuosta varten

mylan ireland limited mylan ireland limited - oxaliplatinum - infuusiokonsentraatti, liuosta varten - 5 mg/ml - oksaliplatiini

Lacosamide UCB Euroopan unioni - suomi - EMA (European Medicines Agency)

lacosamide ucb

ucb pharma s.a. - lakosamidi - epilepsia, osittainen - epilepsialääkkeet, - lakosamidia ucb on tarkoitettu monoterapiana ja lisälääkkeenä hoidettaessa osittainen puhkeamista takavarikot tai eivät ole toissijaisesti yleistyviä aikuisille, nuorille ja lapsille 4-vuotiaille, joilla on epilepsia.

Comirnaty Euroopan unioni - suomi - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Sitagliptin APC Instytut 100 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

sitagliptin apc instytut 100 mg tabletti, kalvopäällysteinen

apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 100 mg - sitagliptiini

Sitagliptin APC Instytut 50 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

sitagliptin apc instytut 50 mg tabletti, kalvopäällysteinen

apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg - sitagliptiini

Sitagliptin APC Instytut 25 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

sitagliptin apc instytut 25 mg tabletti, kalvopäällysteinen

apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 25 mg - sitagliptiini

Abasaglar (previously Abasria) Euroopan unioni - suomi - EMA (European Medicines Agency)

abasaglar (previously abasria)

eli lilly nederland b.v. - glargininsuliini - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellituksen hoito aikuisilla, nuorilla ja yli 2-vuotiailla lapsilla.

Aclasta Euroopan unioni - suomi - EMA (European Medicines Agency)

aclasta

sandoz pharmaceuticals d.d. - zoledronihappoa - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - lääkkeet luusairauksien hoitoon - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. osteoporoosin hoito liittyy pitkän aikavälin systeeminen glukokortikoidi-hoito postmenopausaalisilla naisilla ja miehillä, joilla murtumariski on suurentunut. hoitoon pagetin tauti luu.

Acomplia Euroopan unioni - suomi - EMA (European Medicines Agency)

acomplia

sanofi-aventis - rimonabantti - liikalihavuus - antiobesity preparations, excl. ruokavalion tuotteita - lisänä ruokavalion ja liikunnan lihavien potilaiden (bmi 30 kg/m2) tai sellaisten ylipainoisten potilaiden (bmi 27 kg/m2) liittyy riski tekijä(t), kuten tyypin 2 diabetes tai dyslipidemia (ks. kohta 5.